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Oil-in-water nano-emulsions have been obtained in the HEPES 20 mM buffer 16 
solution / [Alkylamidoammonium:Kolliphor EL=1:1] / [6 weight % ethylcellulose 17 
in ethyl acetate] system over a wide oil-to-surfactant (O/S) range and above 35 18 
weight% aqueous component at 25ºC. The nano-emulsion with an O/S ratio of 19 
70/30 and 95 weight % aqueous component was used for nanoparticles 20 
preparation. These nanoparticles (mean diameter around 90 nm and zeta 21 
potential of +22 mV) were non-toxic to HeLa cells up to a concentration of 3 mM 22 
of cationic species. Successful complexation with an antisense 23 
phosphorothioate oligonucleotide targeting Renilla luciferase mRNA was 24 
achieved at cationic/anionic charge ratios above 16, as confirmed by zeta 25 
potential measurements and an electrophoretic mobility shift assay, provided 26 
that no Fetal Bovine Serum is present in the cell culture medium. Importantly, 27 
Renilla luciferase gene inhibition shows an optimum efficiency (40%) for the 28 
cationic/anionic ratio 28, which makes these complexes promising for “in vitro” 29 
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ABBREVIATIONS LIST 37 
ASO: Antisense oligonucleotide;  CatA: Cationic amidoammonium amphiphile 38 
(ricinoleamidopropyltrimonium methosulfate); CEL:  Kolliphor EL (also known 39 
as Cremophor®EL) ; DLS: Dynamic Light Scattering; DMEM: Dulbecco’s 40 
Modified Eagle’s Medium; EC10: Ethylcellulose; EMSA: Electrophoretic Mobility 41 
Shift Assay; FBS: Fetal Bovine Serum; FDA: Food and Drug Administration; g: 42 
grams; HEPES: 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid; HLB: 43 
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Hydrophilic-Lipophilic Balance; MTT : 3-(4,5- dimethylthiazol-2-yl)-2,5-44 
diphenyltetrazolium bromide; mL: milliliter; mM: millimolar; mRNA: Messenger 45 
ribonucleic acid; mV: millivolts; MW: Molecular Weight; NE: Nano-emulsion; 46 
nM : Nanomolar; NP: Nanoparticle dispersion; N/P ratio : cationic-to-anionic 47 
charge ratio; O/S: Oil-to-surfactant ratio; PBS: Phosphate buffered saline; TBE: 48 




1. INTRODUCTION 53 
Gene delivery is attracting increasing attention for the development of new 54 
therapeutic approaches such as the treatment of diseases considered until now 55 
incurable, and also for diagnostic purposes.  However, nucleic acids are easily 56 
degradable by nucleases and their negative charge and often large size hinder 57 
their cellular uptake. Strategies to overcome low stability and poor cell 58 
penetration ability encompass both, the delivery through nanocarriers and the 59 
synthesis of short chain, chemically modified nucleic acid derivatives. 60 
Nanocarriers may contribute not only enhancing cell penetration but also 61 
allowing the condensation of the genetic material and its protection towards 62 
enzymatic degradation. Moreover, improved cell penetration is also favoured 63 
using shorter nucleic acid chains. In this context, oligonucleotides have been 64 
investigated in recent years, as they are short synthetic single stranded 65 
molecules, generally consisting of 13 to 25 nucleotides (Khvorova et al 2017). In 66 
particular, antisense oligonucleotides (ASOs) can be synthesized with 67 
sequences able to bind to specific mRNA strands preventing its translation into 68 
the proteins they encode, thus reducing, restoring or modifying their expression 69 
(Rinaldi et al. 2018).  This has promoted research as new therapeutic tools 70 
against a large variety of genetic diseases, such as cystic fibrosis (Zamecnik et 71 
al. 2004), amyotrophic lateral sclerosis (Miller et al. 2013), -thalassemia 72 
(Lacerra et al. 2000), familial hypercholesterolemia disease (Wong et al. 2014), 73 
inflammatory bowel diseases (Di Fusco et al. 2019), etc. Since 2016, five 74 
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oligonucleotides have been approved namely for the treatment of hepatic veno-75 
occlusive disease, Duchenne muscular atrophy, spinal muscular atrophy and 76 
hereditary transthyretin amyloidosis (Yin et al. 2019). In addition, numerous 77 
oligonucleotide-based biosensors for in vitro diagnostics and environmental 78 
hazard detection are also being investigated as they are expected to impart 79 
fast, highly specific and sensitive detection (Jung et al. 2016; Platella et al. 80 
2018). To increase their resistance to degradation by nucleases, several 81 
chemical modifications of the sugar ring, the nucleobases or the phosphate 82 
backbone have been proposed so far. Modification of the latter one is quite 83 
common and is often performed by replacing the phosphate group by a 84 
phosphorothioate group, consisting of a sulfur atom attached to the phosphate. 85 
This modification has been demonstrated to provide an increased stability to the 86 
oligonucleotide.  87 
A challenging issue is the design of gene delivery vectors of non-viral origin. 88 
Although viral vectors are highly efficient, they may show safety concerns 89 
(immunogenicity, oncogenesis, etc.) and their production and shelf life is limited. 90 
Therefore, non-viral vectors are preferred (Mintzer et al 2009; Hall et al. 2017; 91 
Olden et al 2018).  However, in spite of their higher loading capacity, they 92 
possess lower transfection efficiency than viral vectors, and the duration of 93 
gene expression is transient. Commercially available lipid-based transfection 94 
agents are frequently used as reference gene delivery vectors but some of them 95 
have been reported to have a negative impact on cell viability and are rather 96 
expensive (Mashal et al. 2017 and 2018; Yang et al. 2014). Therefore other 97 
alternative materials, like carbohydrate polymers have attracted attention, 98 
encompassing chitosan (Rahmani et al. 2019; Csaba et al. 2009; Nafee et al. 99 
2007), amylopectin (Zhou et al. 2012), cationic dextran (Hu el al. 2019) or 100 
starch derivatives (Thiele et al. 2017). Nevertheless, to our best knowledge, 101 
ethylcellulose has not been investigated yet for nucleic acid transfection. The 102 
renewable resources origin, good biocompatibility, easy availability and low cost 103 
of this carbohydrate polymer encourage its use in this field. Ethylcellulose, is a 104 
hydrophobic semi-synthetic cellulose derivative, listed as “generally recognized 105 
as safe” and approved by the FDA for the oral, transdermal and transmucosal 106 
route at daily maximum allowable doses of 308 mg, 80 mg and 50 mg 107 
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respectively (FDA Inactive Ingredient Database; Arca et al. 2018). As a 108 
cellulose derivative, it consists on a linear chain of ß-anhydroglucose units 109 
linked through 1,4-glycosidic bonds. Although this backbone is common to other 110 
cellulose derivatives, like cellulose acetate or nitrocellulose, in ethylcellulose, 111 
the three free hydroxyl groups present in the anhydroglucose unit are partially 112 
substituted by ethoxyl groups. It is worth mentioning that the remaining free 113 
hydroxyls may form hydrogen bonds, favouring intra- and intermolecular 114 
interactions. This strongly influences the physical properties of the polymer and 115 
is exploited for example for the formation of oleogels as fat replacers in food 116 
industry (Aguilar-Zárate et al. 2019). Cellulose derivatives are used in a wide 117 
range of application fields, encompassing ceramics, printing inks, personal care 118 
products, food or pharmaceuticals, to mention a few. A current challenge in the 119 
pharmaceutical field is attaining nanosized structures, as this size range allows 120 
interactions at a subcellular level. Nanostructures of cellulose derivatives can be 121 
prepared both, by top-down and bottom-up techniques. Among top-down 122 
techniques, electrospinning allows attaining a large variety of complex 123 
structures which have demonstrated to be useful for the controlled release of 124 
drugs (Liu et al. 2018; Yang et al. 2019; Wang et al. 2017). As for bottom-up 125 
techniques, the low-energy emulsification approach is an environmentally 126 
friendly method, which has been reported for the preparation of ethylcellulose 127 
nanoparticles (Spernarth et al. 2007; Generalova et al. 2009; Calderó et al. 128 
2011). Although ethylcellulose is nonionic, recently it has been shown that 129 
positively charged ethylcellulose nanoparticle dispersions can be obtained 130 
through nano-emulsion templating in cationic:non-ionic surfactant-based 131 
systems (Leitner et al. 2019; Calderó et al. 2019). These oil-in-water (O/W) 132 
nano-emulsion templates are obtained by a low-energy method and the positive 133 
surface charge of the dispersed systems is attributed to the cationic surfactant. 134 
The surfactant adsorbs at interfaces with the polar head group oriented towards 135 
the aqueous continuous phase of the nano-emulsion. Therefore, the cationic 136 
surfactant provides a positive surface charge to the nano-emulsion drops and 137 
the nanoparticles obtained from them. Positive surface charge provides 138 
ethylcellulose nanomaterials with new potential abilities such as improved 139 
mucoadhesivity, antibacterial properties or enhanced drug loading through 140 
electrostatic interactions.  141 
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The aim of this research work is to investigate for the first time the potential of 142 
positively charged ethylcellulose nanoparticles as antisense oligonucleotide 143 
carriers and transfection agents using a new cationic:non-ionc surfactant 144 
mixture for nano-emulsion templating, with the purpose of attaining optimum 145 
particle size and surface charges for “in vitro” gene delivery. 146 
 147 
 148 
2. EXPERIMENTAL 149 
2.1. Materials 150 
Ethylcellulose, (Figure 1a) a commercial cellulose ether derivative, was from 151 
Colorcon, a distributor of the Dow Chemical Company (ETHOCEL™ Premium 152 
Std 10 ethylcellulose polymer, abbreviated as EC10. ETHOCEL is a trademark 153 
of the Dow Chemical Company). Ethoxyl content was 48.7% and the weight-154 
average molecular weight (Mw) was 66385 ± 322 Dalton with a polydispersity of 155 
4.3 as determined by Gel Permeation Chromatography (Leitner et al. 2019). 156 
Ethyl acetate (> 99.8%) was from Merck. The cationic amidoammonium 157 
amphiphile, ricinoleamidopropyltrimonium methosulfate (Figure 1c), in the 158 
following abbreviated as CatA, was from Evonik. It has an active matter content 159 
of 40 wt% in water and a critical micellar concentration of 3.3 x 10-2 mM 160 
(Burgos-Mármol et al. 2016). Kolliphor EL (also known as Cremophor®EL, from 161 
now on abbreviated as CEL) is a nonionic surfactant (HLB number of 12-14) 162 
manufactured by BASF (Cremophor EL Technical Information, BASF 2004; 163 
Kolliphor Grades. BASF Technical Sheet; Rowe et al. 2009). Water was 164 
deionized and MilliQ® filtered. HEPES salt (4-(2-Hydroxyethyl)piperazine-1-165 
ethanesulfonic acid) was from Sigma Aldrich. It was used to prepare the 166 
HEPES 20 mM buffer which was adjusted at a pH of 7.4. An antisense 167 
phosphorothioate oligonucleotide (MW 5712 g/mol) of 18 nucleotides 168 
complementary to the mRNA of the Renilla luciferase gen, targeting the 169 
luciferase mRNA between positions 20 and 40” was purchased from Proligo 170 
(Sigma–Aldrich, Figure 1b). Lipofectamine 2000 was purchased from 171 
Invitrogen. Dulbecco's Modified Eagle's Medium (DMEM), heat-inactive fetal 172 
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serum bovine (FBS), TRIS-Borate-EDTA (TBE) buffer, PBS buffer, and distilled 173 
water (DNAse/RNAse free) were purchased from Gibco (Waltham, 174 
Massachusetts, USA). Luciferase assay kits were purchased from Promega 175 
(Madison, Wisconsin, USA).  176 
 177 
Figure 1: Chemical structure of a) Ethylcellulose polymer; b) Phosphorothioate 178 
oligonucleotide backbone; c) ricinoleamidopropyltrimonium methosulfate (CatA). 179 
 180 
2.2. Methods 181 
2.2.1. Preparation of oil-in-water (O/W) nano-emulsions 182 
About 4 g of nano-emulsions were prepared in a 5 mL test tube, at a constant 183 
temperature of 25°C by adding HEPES buffer solution dropwise to the mixture 184 
of the oil (6 wt% of ethylcellulose in ethyl acetate) and mixed surfactants (Cat 185 
A:CEL = 1:1), which were previously homogenized. The addition of HEPES 20 186 
mM buffer solution was performed under permanent vortex stirring (Vortex 187 
Genie 2TM, Scientific Industries Inc.) at about 2700 rpm.  188 
 189 
2.2.2. Nano-emulsion domain determination 190 
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The region of formation of O/W nano-emulsion in the HEPES 20 mM buffer 191 
solution / [CatA:CEL = 1:1] / [6 wt% EC10 in ethyl acetate] system was at first 192 
assessed visually at 25°C. Samples with various O/S ratios and HEPES 193 
contents were prepared as described in Section 2.2.1. Compositions with a 194 
translucent to transparent appearance and a reddish or bluish shine when 195 
observed through a lamp light were identified as nano-emulsions. 196 
 197 
2.2.3. Phase Inversion determination 198 
The phase inversion region was determined by conductivity measurements. 199 
Samples (2 g) were prepared by addition of HEPES 20 mM to oil/surfactant 200 
mixtures up to 95 wt%. Electrical conductivity of samples was measured at each 201 
composition by means of a Crison-GLP 31 conductimeter with a Pt/platinized 202 
electrode under continuous magnetic stirring at 25ºC. 203 
 204 
2.2.4. Nanoparticle preparation 205 
Nanoparticles were prepared by the solvent evaporation method using a rotary 206 
evaporator (Büchi) during 45 minutes under reduced pressure of 43 mbar and 207 
at 25°C. The condensator was set at -15ºC with the help of a low-temperature 208 
thermostat (Lauda RE-107 Ecoline Staredition). After evaporation, weight loss 209 
of the sample was replaced with Milli Q® water.  210 
 211 
2.2.5. Nanoparticle:antisense nucleotide complex formation 212 
Nanoparticle:antisense oligonucleotide (ASO) complexes were formed by 213 
adding increasing amounts of nanoparticles to a fixed concentration of ASO in 214 
order to attain the required cationic-to-anionic charge ratios, referred to as N/P 215 
ratios. This ratio is calculated as follows: 216 
𝑁/𝑃 =   
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑠 𝑜𝑓 𝐶𝑎𝑡𝐴




The resulting solutions are vortex mixed, then sonicated in a water bath for 5 218 
minutes at 25ºC to facilitate complex formation and finally incubated at 37ºC for 219 
40 minutes before characterization. 220 
 221 
2.2.6. Particle size characterization 222 
Dynamic light scattering: The mean size of nano-emulsions droplets and 223 
nanoparticles was determined with a 3D-DLS dynamic light scattering 224 
instrument (LS Instruments A. G., Switzerland) equipped with a He-Ne laser 225 
(λ=632.8 nm) and detection limit from 0.5 nm to 5 μm. Measurements were 226 
carried out in triplicate at a scattering angle of 90° and a temperature of 25 °C. 227 
The viscosity of the medium was taken as 0.889 cP. The refractive index of 228 
HEPES 20 mM was 1.334 as determined on an Abbe refractometer (Atago 3T, 229 
Japan) at 25ºC. DLS data were treated by cumulant analysis to obtain the 230 
hydrodynamic radius (Pecora et al. 2000; Brown 1993). 231 
Transmission Electron Microscopy (TEM): Nanoparticle size was also 232 
determined by using the transmission electron microscope JEOL JEM 1010 233 
(Jeol Korea Ltd.), operating at 80 kV. The samples were prepared just after 234 
solvent evaporation. A drop of the nanoparticle dispersion was placed on a 235 
carbon coated copper grid and then negatively stained with 2 wt% uranyl 236 
acetate (UA) solution. About 1000 particles were sized manually from about 50 237 
TEM micrographs taken at different magnifications. For this purpose, the 238 
software package Image J was used. Data were evaluated with the Origin 239 
software package for particle size distribution calculation. 240 
 241 
2.2.7. Shrinking factor determination 242 
The shrinking factor upon nanoparticle formation from the nano-emulsion 243 
droplets was determined as the ratio between the volume of the template nano-244 
emulsion droplet and the volume of the nanoparticle formed. For the calculation 245 
of the respective volumes, the mean hydrodynamic radii, as determined by DLS 246 
(see section 2.2.5.) are used. 247 
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3  248 
where f is the shrinking factor; VNE and VNP are the volumes of a nano-emulsion 249 
drop and a nanoparticle respectively;  𝑟𝑁𝐸 and 𝑟𝑁𝑃 are the mean hydrodynamic 250 
radii or the nano-emulsion and the nanoparticle dispersion, as determined by 251 
DLS. Data are interpreted considering that no droplet size change due to 252 
coalescence, Ostwald ripening or flocculation occurs during solvent evaporation 253 
and that each single nano-emulsion drop generates one nanoparticle. A 254 
shrinking factor of 1 would mean no volume reduction of the template nano-255 
emulsion droplet to form the nanoparticle, thus suggesting that no significant 256 
amount of ethyl acetate is present in the dispersed phase of the nano-emulsion. 257 
 258 
2.2.8. Nano-emulsion and nanoparticle dispersion stability 259 
Nano-emulsion and nanoparticle dispersion stability was assessed both, by 260 
visual observation of phase separation and by light scattering measurements 261 
over several weeks of samples stored at a controlled constant temperature of 262 
25ºC. For the visual assessment, nano-emulsions and nanoparticle dispersions 263 
were considered stable when no macroscopic phases were observed. 264 
 265 
2.2.9. Nano-emulsion and nanoparticle surface charge 266 
The zeta potential, a measure of the net surface charge, was determined from 267 
the electrophoretic mobility measured by laser Doppler velocimetry using a 268 
ZetaSizer Nano Z laser diffractometer (Malvern Instruments), by applying the 269 
Smoluchowsky equation. For the measurements, nano-emulsions and 270 
nanoparticle dispersions were diluted with water to a concentration of 20 mg 271 
sample /g solution. Each sample was measured in triplicate at 25ºC.  272 
 273 
2.2.10. Osmolality determination 274 
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Osmolality was measured on a freezing point osmometer (Micro-Osmometer 275 
Type 15, Löser Messtechnic), allowing measurements in the range from 0 to 276 
2500 mOsm/Kg with a reproducibility of ±0.5%. For the measurements 100 µL 277 
of sample are required. Results are expressed in milliOsmols of solute per 278 
kilogram of solvent (mOsm/Kg). 279 
 280 
2.2.11. Electrophoretic mobility shift assay 281 
Electrophoretic Mobility Shift Assay (EMSA) was used to confirm successful 282 
complex formation between nanoparticles and oligonucleotides. 283 
Phosphorothioate antisense oligonucleotides (0.5 µg) were vortex mixed with 284 
increasing concentrations of the ethylcellulose nanoparticle dispersion in order 285 
to achieve positive to negative nanoparticle-to-oligonucleotide charge ratios 286 
(from now on referred as N/P ratio) between 0 and 30. Mixtures were 287 
subsequently incubated during 40 minutes at 37°C. The complexes were 288 
seeded on a 20 wt% polyacrylamide gel using TBE 1x as running buffer and 289 
subjected to electrophoresis at 150V for 8 hours. Shifts were visualized with a 290 
Gel Logic 200 imaging system after staining the gel with the fluorescent dye 291 
SYBR® Green (TBE 1x 200 mL; 20 µl) for 20 minutes under smooth shaking. 292 
 293 
2.2.12. In vitro cytotoxicity determination 294 
HeLa cells viability in the presence of nanoparticles at different concentrations 295 
was tested using a 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 296 
(MTT) assay. This is a colorimetric assay assessing mainly the mitochondrial 297 
activity. The water-soluble yellow MTT dye undergoes enzymatic reduction by 298 
the dehydrogenase system of alive cells giving rise to water insoluble purple 299 
formazan crystals. For each assay, about 7 x 103 cells/well were seeded on a 300 
96-well plate in 100 µL Dulbecco’s Modified Eagle’s Medium (DMEM) and 301 
cultured for 24 hours. After complete adhesion to the plate, the culture medium 302 
was discarded. Nanoparticle dispersion was added at growing concentrations 303 
between 1.8 and 6.0 mM. The cells were incubated for 4 hours at 37ºC under 304 
5% CO2 atmosphere. Then, the nanoparticle dispersion was discarded and 305 
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DMEM (200 µL) was added. Cells were then further incubated for 15 hours at 306 
37°C. MTT was added at a final concentration of 0.5 mg/mL per (25 µL) and 307 
was incubated for 2 hours at 37°C. Finally, the medium was removed and 200 308 
µL DMSO per well were added to dissolve the purple formazan crystals formed. 309 
Absorbance was measured (Spectra Max M5 by Molecular Devices) at a 310 
wavelength of 570 nm, 30 min after the addition of DMSO. The cell viability was 311 
calculated as a percent ratio of the absorbance of cells treated with nanoparticle 312 
dispersion against the absorbance measured in untreated cells used as control. 313 
Results are expressed as the mean value of nine independent tests carried out 314 
for each concentration.   315 
 316 
2.2.13. Transfection efficiency assay 317 
HeLa cells were cultured at 37ºC, 5% CO2 in DMEM partially supplemented with 318 
10% fetal bovine serum (FBS), 100 µg/mL penicillin and 100 µg/mL 319 
streptomycin. Cells were regularly passaged to maintain exponential growth. 24 320 
hours before transfection at 50 ‒ 80% confluency, cells were trypsinized and 321 
diluted 1:5 with fresh medium without antibiotics (1-3 x 105 cells/mL) and 322 
transferred to 24-well plates (500 µL per well). Two luciferase plasmids, Renilla 323 
luciferase (pRL-TK) and Firefly luciferase (pGL3) from Promega, were used as 324 
reporter and control, respectively. Renilla and Firefly luciferase vectors (0.1 µg 325 
and 1.0 µg per well, respectively) were transfected into the cells using 326 
Lipofectamine 2000 (Invitrogen). Cells were incubated with the plasmids for 6 327 
hours. Medium was discarded and the cells were washed with PBS. Then, 500 328 
µL of fresh medium without antibiotics were added to each well.  Two 329 
transfection experiments were carried out using either DMEM without FBS or 330 
DMEM supplemented with 10% of FBS. The antisense oligonucleotide was 331 
prepared at concentrations of 60, 150 and 270 nm. Nanoparticle:antisense 332 
oligonucleotide complexes which were incubated previously for 40 minutes at 333 
37°C using HEPES (20 mM, pH 7.4) as buffer, were prepared at different 334 
concentrations. 100 µL of sample (naked antisense oligonucleotides (Wild Type, 335 
WT) or nanoparticle:antisense oligonucleotide complexes at the required 336 
concentrations) were added to each well. 22 hours after transfection cell lysates 337 
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were prepared and analyzed using the Dual-Luciferase Reporter Assay System 338 
according to the manufacturer’s protocol. Luminiscence was measured using a 339 
SpectraMax M5 luminometer. As controls, a blank was prepared consisting on 340 
the cell culture transfected with the luciferase vectors in the absence of 341 
nanoparticles and antisense nucleotides and a Wild Type (WT) control, 342 
consisting on the transfected cell culture exposed to the antisense nucleotide in 343 
the absence of the ethylcellulose nanoparticle carrier. Results are calculated as 344 
the normalized ratios between the absorbance measured for the reporter pGL3 345 
gene and the control pRL-TK luciferase gene, and are expressed as the mean 346 




3. RESULTS AND DISCUSSION 351 
 352 
3.1. Ethylcellulose nanoparticle preparation from nano-emulsion 353 
templates 354 
Ethylcellulose nanoparticles have been obtained from nano-emulsion templates 355 
prepared by the phase inversion composition method. For this purpose, first the 356 
oil-in-water (O/W) nano-emulsion domain was determined in the HEPES 20 mM 357 
/ [CatA:CEL = 1:1] / [6 wt% EC10 in ethyl acetate] system, at 25°C. HEPES 20 358 
mM aqueous solution adjusted at a pH value of 7.4 was selected as the 359 
aqueous component for nano-emulsion preparation because it is a particularly 360 
suited buffer in cell culture and hence convenient for the purpose of the current 361 
research work (Ferguson et al. 1980). As shown in Figure 2a, nano-emulsions 362 
form in the oil-to-surfactant (O/S) range between 45/55 and 90/10, above 35 363 
wt% HEPES 20 mM buffer solution content. At higher O/S ratios, the nano-364 
emulsion region stretches to lower aqueous component contents, suggesting 365 
that O/S ratios between 70/30 and 85/15 favor the formation of nano-emulsions. 366 
The formation of the nano-emulsions through phase inversion was confirmed by 367 
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conductivity measurements performed along an experimental path with a 368 
constant O/S ratio (Supplementary Information 1). As shown in Figure 2b, 369 
the nano-emulsions formed display typically a translucent to transparent 370 
appearance, depending on the O/S ratio and the HEPES 20 mM content, with a 371 
bluish shine due to the Tyndall effect. This appearance is strikingly different 372 
from previously reported systems prepared with the same cationic surfactant 373 
(CatA) but different nonionic surfactants (namely Span 80 and Cremophor 374 
WO7) which showed higher opacity (Leitner et al 2019; Calderó et al 2019). It is 375 
also worth mentioning that in the system described herein, the nano-emulsion 376 




Figure 2: a) Oil-in-water (O/W) nano-emulsion domain (coloured area) in the 379 
HEPES 20 mM, pH=7.4 / [CatA:CEL= 1:1] / [6%EC10 in ethyl acetate] system 380 
at 25ºC; b) Visual appearance of the nano-emulsion with an O/S ratio of 70/30 381 
and 95 wt% HEPES content; c) Hydrodynamic diameter (hollow circles) and 382 
zeta potential (filled squares) values of the nano-emulsions with varying oil-to-383 
surfactant (O/S) ratios and a fixed 95 wt% HEPES 20 mM buffer solution 384 
content. 385 
 386 
The nano-emulsions with a 95 wt% of HEPES 20 mM buffer solution content 387 
were selected for further characterization. As shown in Figure 2c, droplet size 388 
of the nano-emulsions did not vary significantly for oil-to-surfactant (O/S) ratios 389 
ranging between 60/40 and 80/20. These display mean diameters around 100 390 
nm. However, at an O/S ratio of 55/45 the droplet diameter is somewhat larger 391 
(around 115 nm). All tested compositions show positive zeta potential values 392 
around 20 mV with a very slight tendency to decrease at increasing O/S ratios. 393 
Interestingly, positively charged ethylcellulose nano-emulsions obtained in 394 
similar systems with the same cationic surfactant but different nonionic 395 
surfactants show considerably larger droplet sizes. Thus, the nano-emulsion 396 
with an O/S ratio of 70/30 and 95 wt% water of the Water / [CatA: Cremophor 397 
WO7 = 1:1]/ [6% EC10 in ethyl acetate] system reported earlier showed a mean 398 
droplet size of around 195 nm and a zeta potential of about 47 mV, both larger 399 
than those of the current system (Calderó et al 2019). In that system, it was 400 
shown that the CatA:Cremophor WO7 ratio had a higher impact on the droplet 401 
size and the zeta potential of the nano-emulsions than the O/S ratio. Also, the 402 
nano-emulsion with the same O/S ratio of 70/30 but 90 wt% water of the Water / 403 
[CatA:Span80= 1:1] / [6% EC10 in ethyl acetate] system at 25ºC, showed a 404 
droplet size above 250 nm and a considerably higher zeta potential (around 55 405 
mV) (Leitner et al 2019). These comparative data suggest that the nonionic 406 
surfactant used in the [CatA:nonionic surfactant] mixture plays a relevant role in 407 
the formation, droplet size and surface charge of the nano-emulsions. It is worth 408 
recalling that no nano-emulsions are formed with CatA in the absence of 409 
nonionic surfactant. In contrast, in systems containing only nonionic surfactant, 410 
ethylcellulose nano-emulsions can be formed (Calderó et al. 2011 and 2016). 411 
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This fact reinforces the idea of the crucial role of the nonionic surfactant in 412 
nano-emulsion formation. Nevertheless, the cationic surfactant is required for 413 
attaining a positive zeta potential, as in systems containing only the nonionic 414 
surfactant the zeta potential is negative, with values typically around –25 mV 415 
(Calderó et al. 2011 and 2016). Another important feature is the preparation 416 
method. Here, the phase inversion composition method is used. No nano-417 
emulsions are formed if the components are mixed at once or following a 418 
different experimental path. Further, the aqueous component may also have an 419 
influence on the nano-emulsion characteristics. In particular, concerning the 420 
surface charge, the zwitterionic species present in the HEPES buffer solution 421 
might exert a neutralizing effect, lowering for that reason the zeta potential 422 
value. 423 
 424 
The visual stability assessment of the nano-emulsion with an O/S ratio of 70/30 425 
and 95 wt% HEPES (from now on designated as NE) revealed no macroscopic 426 
changes over one week at 25ºC. Further, droplet size remained unchanged for 427 
at least 3 weeks at the same storage temperature of 25ºC (Figure 3a). 428 
Therefore, considering the high stability of this nano-emulsion, as well as the 429 
suitable droplet sizes and zeta potential values (about +20 mV), it was selected 430 
for nanoparticles preparation by solvent evaporation. As expected, the 431 
nanoparticle dispersion shows a zeta potential value close to that of its nano-432 
emulsion template, while the mean particle diameter is about 90.8 ± 1.4 nm as 433 
assessed by DLS.  This size is smaller than that of the template nano-emulsion 434 
(96.9 ± 4.6 nm). As polydispersity indexes of both, the nano-emulsion and the 435 
nanoparticle dispersion are high (around 0.4), mean size data should be 436 
considered with caution. However, it should be taken into account that high 437 
polydispersity indexes are usual in dispersed systems prepared with preformed 438 
polymers. An interesting parameter is the calculated shrinking factor of the 439 
nano-emulsion for nanoparticle formation, which here is 1.9. This value is much 440 
higher than expected for a nano-emulsion with 95 wt% aqueous component. In 441 
earlier reported systems, the shrinking factor of nano-emulsions at this aqueous 442 
component content was close to 1, that is, the volume of the nanoparticle and 443 
that of the nano-emulsion drop were very similar (Calderó et al. 2019). The 444 
rather high shrinking factor in the current system suggests that the interfacial 445 
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film in this nano-emulsion might be more efficient in avoiding solvent diffusion 446 
from the dispersed drop to the continuous phase along the dilution path 447 
followed for its preparation, in spite of the more favorable osmotic gradient 448 
expected with HEPES 20 mM buffer solution as compared to water. In fact, the 449 
osmolality of deionized water is zero, while that of the HEPES 20 mM buffer 450 
solution at pH 7.4 used was 33 mOsm/Kg. The visual macroscopic stability of 451 
the nanoparticle dispersion is at least as high as that of the nano-emulsion 452 
template, and particle size remains stable for over 4 weeks when stored at 25ºC 453 
(Figure 3a). The nanoparticles obtained display a globular morphology, as 454 
observed by TEM after negative staining with uranyl acetate solution (Figure 455 
3b). Particle size assessment by image analysis reveals a mean diameter of 456 
about 41 ± 10 nm, that is, roughly half the size measured by DLS. This is 457 
attributed to the fact that the measurements by DLS provide the size of the 458 
solvated particles, while by TEM image analysis the hard sphere size is 459 
measured. In addition, as already mentioned above, the zeta potential value of 460 





Figure 3: a) Particle size as measured by DLS as a function of time of the 466 
nano-emulsion (NE) of the  HEPES 20 mM buffer solution / [CatA:CEL = 1:1] / 467 
[6 wt% EC10 in ethyl acetate] system with an O/S ratio of 70/30 and 95 wt% 468 
HEPES and the nanoparticle dispersion (NP) obtained from the nano-emulsion 469 
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3.2. Formation and characterization of ethylcellulose 476 
nanoparticles:oligonucleotide complexes  477 
 478 
The formation of complexes of the positively charged ethylcellulose 479 
nanoparticles with an antisense oligonucleotide (ASO) was studied. The ASO 480 
are negatively charged due to the presence of phosphorothioate groups in the 481 
molecule backbone (Figure 1b). Increasing amounts of nanoparticle dispersion 482 
were added to a fixed concentration of ASO, as explained in detail in the 483 
experimental section, in order to attain cationic (nanoparticles)-to-anionic (ASO) 484 
charge ratios (N/P) ranging from 0 to 30. As shown in Figure 4a, the 485 
nanoparticles:ASO complex size kept roughly constant around 90 nm, 486 
regardless the N/P ratio. In the absence of ASO, the nanoparticles show a 487 
mean size of 90.8 nm as measured by DLS and a zeta potential value of +22.0 488 
mV.  Although it might be expected that complex size is larger than the bare 489 
nanoparticles, this is not observed here. This might be explained by a 490 
compaction due to electrostatic interaction, and may also be considered as a 491 
sign that no instability by aggregation has occurred (Li et al. 2011; Puras et al. 492 
2014; Rahmani et al. 2019). It is also worth mentioning that the size range, 493 
which is below 200 nm, is within that reported as appropriate for cell membrane 494 
penetration (Davis et al. 2009; Yasar et al. 2018).  495 
Zeta potential values are negative when the naked oligonucleotide (without the 496 
nanoparticles) is present (N/P ratio 0, about -15 mV), which is due to the 497 
negative phosphate groups in the backbone of the oligonucleotide. Surface 498 
charge values remain in this range up to N/P ratio 8. At N/P ratios ≥ 8, a 499 
pronounced increase to almost neutral zeta potential values takes place. This 500 
behavior is generally recognized as an indication of electrostatic interactions 501 
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between the negatively charged species and the positively charged 502 
nanoparticles (Ogris et al. 1999; Putnam et al. 2001; Davis et al. 2009; Hartl et 503 
al. 2019). At N/P ratios ≥ 16, surface charge values reach a plateau (neutral or 504 
slightly negative values). At these N/P ratios it is assumed that full complexation 505 
is achieved. Although the long-term stability of the nanoparticles:ASO 506 
complexes has not been determined, these did not show signs of instability 507 
during the experimental time. Stability may be favoured by their small size 508 




Figure 4: a) Size (empty circles) and zeta potential (black squares) values as a 513 
function of the N/P ratio of complexes formed between nanoparticles and the 514 
antisense oligonucleotide (ASO) phosphorothioate, at 25°C; b) EMSA gel shift 515 
assay obtained after 8 hours, to analyse the ability of the nanoparticles to form 516 
complexes with the antisense oligonucleotide (ASO) phosphorothioate. The 517 
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mobility of ASO is retarded upon complexation causing the fading away of the 518 
band of stained ASO in the polyacrylamide gel at increasing N/P ratio, indicating 519 
successful nanoparticles:ASO complex formation; c) Schematic illustration of a 520 
nanoparticle:ASO complex. Nanoparticles were obtained from nano-emulsions 521 
of the HEPES solution / CatA:CEL = 1:1] / [6 wt% EC10 in ethyl acetate] system 522 
with an O/S ratio of 70/30 and 95 wt% HEPES solution 523 
 524 
 525 
The surface charge of the complexes was also measured in the presence of 526 
Fetal Bovine Serum (FBS) which is frequently used in transfection studies, as 527 
an approach to physiological conditions encountered in “in vivo” environments. 528 
It is well known that in biological media nanoparticles undergo a coating 529 
process mainly by adsorption of proteins forming a layer designated as “protein 530 
corona”. This protein corona endows nanoparticles with a new biological identity 531 
which determines its physiological impact, such as immune response and 532 
hence blood clearance rate, biodistribution, cell penetration, interaction with 533 
receptors, etc. (Monopoli et al. 2012). As illustrated in the Supplementary 534 
Information 2, in the presence of FBS, nanoparticle:ASO complexes displayed 535 
a negative zeta potential at all N/P charge ratios studied. Zeta potential values 536 
are more negative when oligonucleotide and serum without nanoparticles are 537 
present (N/P ratio 0, about -25 mV) as additional negative charges coming from 538 
serum proteins are present. Surface charge values increase up to -15 mV for 539 
N/P ratio 8 and then only slightly for N/P ratios > 8, staying in the negative 540 
range (about -10 mV). These results suggest that negatively charged 541 
components in serum were, depending on the charge ratio, presumably 542 
adsorbed onto the surface of the nanoparticle complexes. Similar results are 543 
reported by Li et al. (Li et al. 2011), who found that the zeta potential values of 544 
liposome/DNA complexes (lipoplexes) in the absence of serum were positive 545 
and increased with increasing N/P ratio. In the presence of serum, however, 546 
lipoplexes displayed negative zeta potential values at all studied N/P ratios 547 
which was attributed to negatively charged components in serum adsorbed onto 548 
the surface of the lipoplex particles. Interestingly, other studies carried out by 549 
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means of zeta potential isotherms on the adsorption of bovine serum albumin 550 
(BSA) onto differently functionalized PLGA nanoparticles revealed that upon 551 
saturation of the nanoparticle surface with BSA, the zeta potential value 552 
remained constant at approximately – 10 mV (Fornaguera et al. 2015). This 553 
suggests that the constant value around -10 mV attained here regardless the 554 
N/P ratio may be attributed to complex surface saturation with serum proteins. It 555 
is also worth recalling that albumin is the main protein in serum. 556 
To further confirm the complex formation between nanoparticles and ASO, 557 
electrophoretic mobility shift assays (EMSA) were performed. This experiment 558 
was carried out without FBS and as described in Section 2.2.11. Figure 4b 559 
shows the results obtained. The mobility of ASO in the polyacrylamide gel is 560 
retarded upon complexation with the nanoparticles, which is detected by a shift 561 
and fading away of the band of the stained ASO at increasing N/P ratio, 562 
indicating successful nanoparticles:ASO complex formation The numbers 563 
between the vertical lines in the figure indicate the N/P ratio. The negative 564 
control is designated 0, i.e. it contains only ASO. With increasing N/P ratio, the 565 
band gets broader which was assumed to be due to the formation of complexes 566 
with different sizes (polydispersity). For the N/P ratio 20 the band is less intense 567 
than for smaller N/P ratios and the higher the N/P ratio is, the more fades the 568 
band. The fading of the band is interpreted as a sign of complex formation and 569 
retardation (Lundberg et al. 2007). These EMSA results are in good agreement 570 
with those obtained from surface charge measurements (Figure 6a), both 571 
suggesting that complex formation is achieved at N/P ratios ≥ 16. This N/P ratio 572 
is comparable to that reported for other gene delivery systems (Lee et al. 2016). 573 
Figure 5 shows a TEM micrograph obtained from the nanoparticle:ASO 574 
complex with an N/P ratio of 30, the highest studied N/P ratio in which 575 
complexation took place. Complexes showed a rounded shape, similar to that 576 
observed for pristine nanoparticles, and have a mean size of 30 nm (by TEM 577 
image analysis). This value differs significantly from that obtained by DLS 578 
(about 90 nm). As mentioned previously, the sizes measured from TEM 579 
micrographs correspond to the hard sphere sizes while DLS provides sizes of 580 
the solvated complexes. Also the high polydispersity (>0.4 by DLS) has to be 581 
taken into account. Figure 5b compares the size distributions of the 582 
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nanoparticle dispersion and the nanoparticle:ASO complex. Both size 583 
distributions are monomodal. The main population of the bare nanoparticle 584 
dispersion is at 40 nm and is shifted towards smaller sizes when the complex 585 
with ASO is formed. This decrease in mean size has to be taken with caution as 586 
the polydispersity in both systems is rather high. However, it should be also 587 
considered that electrostatic interactions may favour the compaction of the 588 
structure, thus yielding smaller entities. 589 
 590 
 591 
Figure 5: a) TEM micrograph of the negatively stained complex between the 592 
nanoparticle dispersion and the antisense oligonucleotide phosphorothioate, at 593 
the N/P ratio 30. Nanoparticles were obtained from a nano-emulsion of the 594 
HEPES 20 mM solution / [CatA:CEL = 1:1] / [6wt% EC10 in ethyl acetate] 595 
system with an O/S ratio of 70/30 and 95 wt% HEPES solution; b) Complex size 596 
distributions, assessed from TEM image analysis, of a negatively stained 597 
nanoparticle dispersion and of the complex between nanoparticles and the 598 
antisense oligonucleotide phosphorothioate, at the N/P ratio 30. Nanoparticles 599 
were obtained from nano-emulsions of the HEPES solution / CatA:CEL = 1:1] / 600 
[6 wt% EC10 in ethyl acetate] system with an O/S ratio of 70/30 and 95 wt% 601 
HEPES solution 602 
 603 
 604 
3.3. Biological characterization 605 
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The nanoparticle dispersion of the HEPES 20 mM solution / [CatA:CEL = 1:1] / 606 
[6 wt% EC10 in ethyl acetate] system with an O/S ratio of 70/30 and 95 wt% 607 
HEPES solution selected for the complexation studies was further investigated 608 
to determine its toxicity and transfection efficiency.  609 
 610 
3.3.1. Cytotoxicity assessment by the MTT assay 611 
The viability and proliferation of HeLa cells in the presence of nanoparticles was 612 
evaluated by performing the MTT cytotoxicity assay on HeLa cells. The studies 613 
were carried out as described in Section 2.2.12. The absorbance of the colored 614 
complex solutions was measured at a wavelength of 570 nm and graphically 615 
represented as a function of cationic species concentration present in CatA (40 616 
wt% of active matter), as shown in Figure 6. Keeping in mind that cell viability is 617 
directly proportional to the amount of formazan produced by the enzymatic 618 
activity of living cells, the measured absorbance gives an idea of the number of 619 
viable cells when compared with the control (i.e. here cells in the absence of 620 
nanoparticles).  621 
 622 
 623 
Figure 6: Cell viability (%) of HeLa cells as a function of nanoparticle 624 
concentration after 4 hours of treatment. The blank bar indicates the sample 625 
without nanoparticles. 626 
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The graphic shows that cell viability decreases slightly at 3 mM with respect to 627 
the blank while at higher concentration it is considerably reduced, indicating that 628 
no cytotoxicity occurs up to a concentration of 3 mM, referred to the cationic 629 
species. It is well known that generally, cytotoxicity increases with increasing 630 
cationic charge. The behavior displayed by our positively charged nanoparticles 631 
is in good agreement with other studies carried out with cationic nanoparticles, 632 
which showed increased cytotoxicity with increasing concentration of cationic 633 
polymer (Putnam et al 2001).  634 
 635 
 636 
3.3.2. Transfection efficiency of nanoparticle:oligonucleotide complexes 637 
The ability of the cationic nanoparticles to form complexes with the antisense 638 
oligonucleotide (ASO) phosphorothioate through electrostatic interactions has 639 
been described and proved in the previous sections. As mentioned, the ASO 640 
chosen for our study inhibits the Renilla luciferase gene. The transfection 641 
efficiency of the nanoparticles:ASO complexes in the absence and presence of 642 
Fetal Bovine Serum (FBS) has been evaluated. At first, the optimal ratio 643 
between the antisense oligonucleotide and the nanoparticles was determined. 644 
For this purpose, cells were cotransfected with two luciferase plasmids (Renilla 645 
and Firefly; target and internal control, respectively). Then both, the naked 646 
antisense oligonucleotide designed to inhibit the expression of Renilla luciferase 647 
gene as well as the nanoparticle:ASO complexes were added to the transfected 648 
cells in the presence and absence of fetal bovine serum. After 24 hours 649 
incubation, the luciferase activities of the samples were measured by using a 650 
luminometer. Figure 7a plots the Renilla luciferase activity normalized to Firefly 651 
luciferase as a function of the nanoparticle to ASO charge ratio (N/P), keeping a 652 
constant ASO concentration of 60 nM in the absence of serum. As inferred from 653 
the zeta potential values and the electrophoretic mobility shift assay shown 654 
before, formation of nanoparticle:ASO complexes took place at N/P ratios equal 655 
to or above 16 (Figure 4a). As full complexation was assumed in the plateau 656 
range of zeta potential, which was confirmed by gel shift assays (Figure 4b), 657 
two N/P ratios of the plateau range (N/P 28 and 30) were selected for 658 
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transfection assays and a N/P ratio higher than those studied (N/P 35) in order 659 
to study the influence of higher complex ratios. It is worth mentioning that 660 
several authors have reported the ability of some antisense oligonucleotides to 661 
penetrate into the cells through their membrane without the help of transfection 662 
agents, by a process called gymnosis (Stein et al. 2010; Moschos et al. 2011 ; 663 
Martirosyan 2018). Nevertheless, previous reported experiments have 664 
discarded this cell entry capability for the ASO studied here (Fornaguera et al. 665 
2015b; Mayr et al. 2017). In addition, as shown in Figures 7a and 7b, the 666 
luciferase activity of the transfected HeLa cells in the absence (Blank) and the 667 
presence of the antisense oligonucleotide (Wild Type) were similar and close to 668 
unity. This result confirms that the oligonucleotide alone is not able to reach the 669 
cytoplasm of the HeLa cells to inhibit the expression of the Renilla luciferase 670 
gene. However, it was found that the nanoparticles:ASO complexes were able 671 
to transfect the antisense oligonucleotide as the expression of Renilla luciferase 672 
gene was specifically inhibited. The highest inhibitory properties were found 673 
with nanoparticle:antisense oligonucleotide complexes at the charge ratio of 674 
N/P 28 obtaining around 40% inhibition efficiency in serum-free medium. 675 
Reported values of Renilla luciferase silencing in HeLa cells by Lipofectamine 676 
2000 (frequently used as a positive control reference) are around 84% for at an 677 
ASO concentration of 60 nM, and below 60% for cationic surfactant vesicles at 678 
ASO concentrations above 60 nM (Grijalvo et al. 2014; Mayr et al. 2017).  The 679 
inhibition efficiency of our nanoparticle:antisense oligonucleotide complex is 680 
similar to that of dendronized poly(lactic-co-glycolic) acid nanoparticles 681 
functionalized with third generation cationic dendrons (around 40% inhibition) 682 
and higher than that of nanoparticles functionalized with second generation 683 
cationic dendrons (about 20% inhibition) at the same 60 nM ASO concentration, 684 
although for these both carriers the N/P ratio is much lower (0.75/1) due to the 685 
high positive charge density on the dendron distal surface (Fornaguera et al. 686 
2015b). 687 
Surprisingly, higher N/P ratios in our nanoparticle:ASO complexes did not 688 
provide improved transfection efficiency. Thus, N/P charge ratios of 30 only 689 
produced a knockdown value of about 11%. This might be attributed to a 690 
stronger binding of the ASO to the positively charged nanoparticle, hence 691 
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reducing the release of the ASO. Several authors have reported that an 692 
optimum balance between nucleic acid complexation and release from their 693 
carrier is required for an efficient transfection (Pacharoenchai et al. 2012; Puras 694 
et al. 2014). It is also worth noticing that the luciferase activity at the N/P ratio of 695 
35 exceeded that of the blank and the naked ASO (WT). This effect has been 696 
described in other non-viral vectors, such as proline-rich cell-penetrating 697 
peptides (Grijalvo et al. 2012), dendronized PLGA nanoparticles (Fornaguera et 698 
al. 2015b) or cationic vesicles (Mayr et al. 2017). Although in our study the 699 
complex size did not vary significantly in the N/P range studied, complex 700 
aggregation phenomena in the cellular environment may not be ruled out, thus 701 
hindering their penetration into the cell, as pointed out by several authors (Xiong 702 
et al. 2011; Mayr et al. 2017). For this reason, the N/P ratio of 28 was 703 
considered to be the optimal for transfecting antisense oligonucleotides with 704 
these nanoparticles:ASO complexes in the experimental conditions tested.  705 
 706 
Figure 7: a) Gene-specific silencing activities for phosphorothioate antisense 707 
oligonucleotide, targeting the Renilla luciferase mRNA expressed in HeLa cells. 708 
a) In serum-free medium. The N/P (nanoparticle:antisense oligonucleotide) 709 
ratios tested for gene knockdown were N/P 28, 30 and 35. The ASO 710 
concentration was 60 nM. b) In medium supplemented with 10% serum for 711 
unmodified phosphorothioate antisense oligonucleotide (WT) at different 712 
concentrations (60, 150 and 270 nM) and for the nanoparticle:ASO complexes 713 
at N/P ratio 28 (nanoparticle:antisense oligonucleotide) using mentioned ASO 714 
concentrations. The bar named Blank is the result of luciferase activity of the 715 
HeLa cells with the two transfected plasmids. The bar named WT is the result 716 




In addition the transfection of HeLa cells was also tested in cell culture media 719 
supplemented with fetal bovine serum. This allows simulating more closely 720 
physiological conditions, with the aim to assessing the possibility of being used 721 
in vivo, where high concentrations of numerous proteins are encountered. For 722 
this study, the N/P charge ratio of the complex was set at 28 as it was judged to 723 
be the optimal for transfection in the absence of serum. In addition, ASO 724 
concentrations above 60 nM (namely 150 and 270 nM) were also tested. As 725 
shown is Figure 7b, the normalized luciferase activity was around 1 for all 726 
tested samples, which implies that no gene silencing was detected in the 727 
presence of serum. Several factors may account for the lack of inhibition of the 728 
luciferase expression, such as the coating of the complex with serum proteins, 729 
the displacement of the ASO by serum proteins and lipoproteins, thus reducing 730 
or even completely quenching the ASO binding to the positively charged 731 
nanoparticles or the increased electrostatic interactions between the 732 
nanoparticles:ASO complexes and serum components giving rise to large 733 
aggregates unable to penetrate into the cells. These transfection efficiency 734 
results in the presence of FBS preclude the use of these nanoparticles:ASO 735 
complexes for in vivo experiments. However, they can be used for gene 736 




4. CONCLUSIONS 741 
Positively charged ethylcellulose nano-emulsions have been obtained in the 742 
HEPES 20 mM buffer solution / [CatA:CEL = 1:1] / [6 wt% EC10 in ethyl 743 
acetate] system. These nano-emulsions as well as the nanoparticles obtained 744 
from them show smaller sizes than those described earlier in similar systems. 745 
The nanoparticles have a convenient biocompatibility profile and in spite of their 746 
moderate positive surface charge (around + 20 mV), successful complexation 747 
with an antisense oligonucleotide (ASO) has been achieved. In vitro transfection 748 
28 
 
tests revealed that although in the presence of serum no gene silencing was 749 
detected, optimum transfection efficiency (40%) was achieved at N/P ratio 28 in 750 
serum-free medium. These results encourage further research on the use of 751 
these complexes for in vitro diagnostic tests as well as in vivo gene therapy 752 
using administration routes in which the impact of the adhesion of proteins 753 
present in the medium is expected to be lower than in the parenteral 754 
environment, such as the dermal or inner ear route of administration.   755 
 756 
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SUPPLEMENTARY INFORMATION 998 
 999 
Supplementary Information 1 1000 
Conductivity as a function of total aqueous solution content in the HEPES 20 1001 
mM / [CaA:CEL = 1:1] / [6 wt% EC10 in ethyl acetate] system along the dilution 1002 
path with the O/S ratio of 70/30 at 25ºC. 1003 
 1004 
As shown, the conductivity values increase at increasing aqueous solution 1005 
content and reach a maximum, which in this system is produced at about 1500 1006 
µS/cm. Then conductivity values gradually decrease due to the effect of dilution 1007 
of the conducting species. It is worth mentioning that HEPES solution contains 1008 
zwitterionic molecules. The conductivity values attained, as well as the 1009 
conductivity variation as a function of the aqueous component content are 1010 
comparable to those obtained with similar systems described earlier, containing 1011 
the same cationic surfactant but different nonionic surfactants, namely Span 80 1012 
(Leitner et al. 2019) and Cremophor WO7 (Calderó et al. 2019). Phase 1013 
inversion takes place at about 25 wt% HEPES solution. 1014 
 1015 
 1016 
Supplementary Information 2 1017 
Zeta potential values as a function of the N/P ratio of complexes formed 1018 
between nanoparticles and the antisense oligonucleotide (ASO) 1019 
38 
 
phosphorothioate in the presence of Fetal Bovine Serum (FBS), at 25°C. 1020 
Nanoparticles were obtained from nano-emulsions of the HEPES solution / 1021 
[CatA:CEL = 1:1] / [6 wt% EC10 in ethyl acetate] system with an O/S ratio of 1022 
70/30 and 95 wt% HEPES solution. 1023 
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